Plastic Surgery Industry Stocks( $NBIX, $ALKS, $NEPT...) Post Strong Weekly Gains, Average Increase of 9.38%💰
In the world of biopharmaceutical companies specializing in surgeries and treatments for diseases like solid tumors, cancers, and hematologic malignancies, a select group of stocks has been making waves. These companies not only perform critical surgeries but also provide essential inputs such as sterile biological implants. Among the notable stocks in this theme are Aravive, Neurocrine Biosciences, and RTI Surgical Holdings.
🌐Tickers in Industry - $NBIX, $ALKS, $NEPT, $CYCCP, $EVGN, $SIEN, $ZBH, $SYRS, $ARAV
Market Cap
The average market capitalization across the plastic surgery theme stands at a substantial $4.6 billion. However, within this theme, there's a wide range of valuations, with individual tickers ranging from $220.4 thousand to a whopping $22.1 billion. Zimmer Biomet Holdings (ZBH) holds the distinction of being the highest-valued company in this group, while SRGAQ is at the other end of the spectrum with a valuation of $220.4 thousand.
High and Low Price Notable News
In the last week, stocks within the plastic surgery theme exhibited significant price movement. On average, the weekly price growth for these stocks was an impressive 9.36%. This strong performance is in stark contrast to the average monthly price growth, which recorded a decline of -8.15%, and the average quarterly price growth, which experienced a substantial drop of -30.27%.
CYCCP was the standout performer, experiencing the highest price growth at 50.77%. In contrast, SYRS faced the biggest decline in stock price, falling by -7.8%. It's essential to note that the plastic surgery theme appears to be more resilient on a shorter-term basis, as evidenced by the strong weekly performance.
Volume
The average weekly volume growth across all stocks in the plastic surgery theme saw a decrease of -9.53%. For the same set of stocks within the theme, the average monthly volume growth declined even further, with a significant drop of -42.5%. However, the average quarterly volume growth bucked this trend, recording a healthy increase of 39.34%.
Notably, some individual stocks experienced remarkable volume spikes on specific days. For instance, Sientra (SIEN) saw its volume surge over two consecutive days, resulting in a record-breaking daily growth of 185% of the 65-Day Volume Moving Average. Aravive also had a remarkable day, with its volume surging and achieving a record-breaking daily growth of 386% of the 65-Day Volume Moving Average. Neptune Wellness Solutions also stood out with an astonishing one-day increase of 4,646% of the 65-Day Volume Moving Average.
Fundamental Analysis Ratings
While the provided data doesn't include fundamental analysis ratings, it is worth mentioning that in the world of biopharmaceutical companies specializing in surgeries and treatments, fundamental analysis plays a crucial role in evaluating their long-term prospects. Investors interested in these stocks should consider conducting a thorough fundamental analysis to gauge factors such as revenue, earnings, competitive positioning, and growth potential.
The plastic surgery industry stocks have shown remarkable strength in the last week, with an average gain of 9.38%. Despite some challenges in longer-term price and volume trends, the theme remains an area of interest for investors, with individual stocks exhibiting noteworthy performance. As always, it's essential for investors to conduct their due diligence and consider both technical and fundamental factors when evaluating potential investments in this dynamic sector.
NBIX : NBIX is on the rise, with its 10-day Moving Average crossing above the 50-day moving average on November 13, 2023. This bullish crossover signals an upward shift in the trend, potentially making it an opportune time to consider buying. Historical data reveals that in 11 out of 12 similar instances in the past, when the 10-day surpassed the 50-day, the stock continued its ascent over the subsequent month. With a strong track record, there's a 90% chance of the upward trend persisting, presenting an encouraging outlook for NBIX.
ALKS : ALKS has shown a promising development as its RSI Oscillator broke out of oversold territory on October 26, 2023. This shift suggests a potential transition from a bearish trend to a bullish one, making it an intriguing opportunity for traders. Considering historical data, the A.I.dvisor analyzed 25 comparable instances where the indicator exited oversold territory, revealing that in 22 of those cases, the stock experienced upward movement. This compelling track record implies an 88% probability of a continued uptrend, offering traders a favorable outlook for ALKS. Investors may consider taking positions in the stock or call options to capitalize on this potential upswing.
NEPT : NEPT has registered a positive turn in its Moving Average Convergence Divergence (MACD) Histogram, effective October 11, 2023. This pivotal shift often indicates a potential upward trajectory for the stock. A historical analysis reveals that in 39 out of 46 instances when NEPT's MACD turned positive, the stock continued its ascent over the subsequent month. With an 85% probability of a sustained upward trend, investors should take note of this promising signal and consider their investment strategy accordingly. NEPT may present an appealing opportunity for those seeking to capitalize on the potential price appreciation in the coming weeks.
NBIX in +5.43% Uptrend, advancing for three consecutive days on April 17, 2025
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NBIX advanced for three days, in of 299 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NBIX's RSI Oscillator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for NBIX just turned positive on April 16, 2025. Looking at past instances where NBIX's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .
NBIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on March 31, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NBIX as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The 50-day moving average for NBIX moved below the 200-day moving average on March 13, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for NBIX entered a downward trend on April 07, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.297) is normal, around the industry mean (61.171). P/E Ratio (57.202) is within average values for comparable stocks, (90.174). Projected Growth (PEG Ratio) (0.464) is also within normal values, averaging (2.987). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (7.564) is also within normal values, averaging (20.123).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NBIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NBIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a product based biopharmaceutical company
Industry PharmaceuticalsOther